A Study to Compare the Tolerability of Microencapsulated Iron Compared to a Conventional Iron Supplement in the Market

Supplement Clinical Trial

— IRON  

Official title:

A Randomized, Double Blind, Crossover Study to Compare the Tolerability of Microencapsulated Iron Compared to a Conventional Iron Supplement in the Market

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04199234
• Other study ID #: UCAMCFE-0011
• Status: Completed
• Phase: N/A
• Start date: February 1, 2020
• Est. completion date: March 8, 2021

Study information

• Verified date: March 2020
• Source: Universidad Católica San Antonio de Murcia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the frequency of appearance of the total clinical manifestations (expected adverse event: nausea, vomiting, heartburn, abdominal pain, gas/swelling, diarrhea, headache, shortness of breath, metallic taste and constipation) after consuming microencapsulated iron and comparator for 14 days.

Description:

Subjects will consume a daily dose once per day for 14 days with a washout period of two menstrual cycles between the two products. After this washout period, subjects will return to the clinical and will undergo identical procedures with counter order of the intervention. Each day of the study will be recorded in a diary by each subject. Participants will be requested not to change their regular life habits and diet during the entire study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: March 8, 2021
• Est. primary completion date: December 23, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion criteria:

• Healthy premenopausal women (Age: 18-50)
• Not anemic
• Normal Iron status: hemoglobin (>12 g/dL)
• Normal BMI (20-25 kg/m²)
• Normal blood profile at screening: Complete blood count, platelets, Glucose, HbA1c, Electrolytes (Na, K, Cl), AST, ALT, bilirubin, y-GT), Creatinine, eGFR, blood urea nitrogen, uric acid, Total protein (albumin/ globulin)
• Subject is in good physical health as established by medical history, vital signs, physical examination and electrocardiogram (ECG)
• Normal urine profile at screening: pH, protein, glucose, nitrite, ketone, bilirubin, urobilinogen, red blood cells, leukocytes, creatinine, sediments, absence of bacteria
• Regular menstrual cycle (28 +/- 5)
• Willingness not to change eating habits (do not start/ change of diet) and general habits (stop smoking) for the duration of the study
• C-reactive protein: < 5mg/L.

Exclusion Criteria:

• Previous participation in iron tolerability trials.
• Participation in a clinical research trial within 30 days prior to randomization
• Chronic medication (except oral contraceptives)
• Pregnancy or lactation
• Hb levels < 12g/dL (women) (anemia)
• Reported chronic disease
• Infectious disease
• Alcohol or drug abuse
• Hyperlipidemia as defined by LDL > 3.36 mmol/L (130 mg/dL) and/or triglycerides > 2.26 mmol/L (200 mg/dL).
• Relevant co-morbidities: Gastrointestinal disease such as peptic ulcer, enteritis, or ulcerative colitis, inflammation, pre-existing poorabsorption or liver disease, kidney disease, iron-storage disorders such as hemochromatosis, haemosiderosis, or chronic autoimmune inflammatory condition
• Serious illness that may confound study results or interfere with compliance
• Any other laboratory abnormality, medical condition or psychiatric disorder which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
• Known intolerance to oral iron supplements
• Intake of iron suppl. and/or multivitamins containing iron during the last three months before study entry
• Use of any mineral/vitamin or other supplements during the past month prior to study
• Subject has a known allergy to the test material's active or inactive ingredients
• Individuals who are cognitively impaired and/or who are unable to give informed consent
• Any active medical illness in last 48 h
• Sexually-active females who are not willing to use an effective form of birth control.
• Subjects with severe premenstrual symptoms (PMS)
• Subjects that have followed specific diet, eg. high protein diet, within 30 days prior to study start
• Previous gastric bypass, sleeve gastrectomy, or gastric band surgery
• Blood donation within the previous 1 months.

Related Conditions & MeSH terms

• Supplement

Intervention

Dietary Supplement:
• Experimental product consumption
Consumption of an encapsulated iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
• Comparator product consumption (Iron sulphate)
Consumption of iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch

Locations

Country	Name	City	State
Spain	Catholic University of Murcia	Murcia

Sponsors (1)

Lead Sponsor	Collaborator
Universidad Católica San Antonio de Murcia

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of appearance of the total clinical manifestations due to the consumption of both products	The proportion of participants that reported at least one adverse event, which refers to the total of clinical manifestations due to the consumption of both products. Symptoms that were considered: nausea, heartburn, abdominal pain, gas/swelling, diarrhea, vomits, metallic taste, constipation, headache and respiratory distress.	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Frequency of appearance of each of the total clinical manifestations due to the consumption of both products	The proportion of participants that reported at least one adverse event, which refers to each of the total of clinical manifestations due to the consumption of both products (individual symptoms that were considered: nausea, heartburn, abdominal pain, gas/swelling, diarrhea, vomits, metallic taste, constipation, headache and respiratory distress)	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Change in the total number of incidences/complaints related to the study product	Symptoms: nausea, heartburn, abdominal pain, gas/swelling, diarrhea, vomits, metallic taste, constipation, headache, and respiratory distress	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Number of clinical manifestations that subjects experience	Symptoms: nausea, heartburn, abdominal pain, gas/swelling, diarrhea, vomits, metallic taste, constipation, headache, and respiratory distress	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Overall intensity of clinical manifestations that subjects experience (nausea, heartburn, abdominal pain, gas/swelling)	Intensity was measured with VAS scale	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Overall intensity of clinical manifestations that subjects experience (diarrhea and vomits)	Intensity was measured with number of times.	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Change in the acute intensity of adverse effects that subjects experience	Symptoms: Nausea, heartburn, abdominal pain, gas/swelling, vomits, diarrhea, constipation, metallic taste, headache, and respiratory distress	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Duration (number of days) of clinical manifestation	This variable was measured in total duration (number of days) of symptom onset (symptoms: nausea, heartburn, abdominal pain, metallic taste, headache, diarrhea, constipation, gas/swelling, respiratory distress and vomits)	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Duration (minutes per day) of clinical manifestation	Daily duration (minutes) of symptom (nausea, heartburn, abdominal pain, gas, metallic taste, headache, and respiratory distress)	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Health status using VAS scale	Health status (daily and with respect to the previous day)	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Physical activity	Proportion of participants that experienced any impact on daily activity	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Bowel movements	Number of times subjects go to the toilet.	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Stool morphology	Stool type (Bristol scale)	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Sleep quality	Sleep quality measured on a scale of 1 to 5 (1 being poor sleep quality and 5 being very good sleep quality).	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Sleep duration	Number of hours subjects sleep	This variable will measure the changes in clinical manifestations during the period of each of the intakes, i.e., for 14 days, and during the washout period.
Secondary	Ferritin	Iron profile. By means of a blood draw.	Day 1 and day 14 of each product consumption.
Secondary	Saturated transferrin	Iron profile. By means of a blood draw.	Day 1 and day 14 of each product consumption.
Secondary	Serum iron	Iron profile. By means of a blood draw.	Day 1 and day 14 of each product consumption.
Secondary	Hemoglobin	Iron profile. By means of a blood draw.	Day 1 and day 14 of each product consumption.
Secondary	Safety variables	Safety parameters (physical examination, vital signs, blood and urine laboratory tests, adverse events other than expected in the study)	Day 1 and day 14 of each product consumption.